Clinical and functional consequences of anti-properdin autoantibodies in patients with lupus nephritis.
Adult
Antibodies, Antinuclear
/ blood
Antigen-Antibody Complex
/ metabolism
Autoantibodies
/ blood
Cohort Studies
Complement C3
/ metabolism
Complement C4
/ metabolism
Disease Progression
Humans
Immunoglobulin G
/ blood
Kidney
/ metabolism
Lupus Erythematosus, Systemic
/ immunology
Lupus Nephritis
/ immunology
Predictive Value of Tests
Properdin
/ immunology
complement
lupus nephritis
properdin
Journal
Clinical and experimental immunology
ISSN: 1365-2249
Titre abrégé: Clin Exp Immunol
Pays: England
ID NLM: 0057202
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
23
03
2020
revised:
08
04
2020
accepted:
09
04
2020
pubmed:
20
4
2020
medline:
20
1
2021
entrez:
20
4
2020
Statut:
ppublish
Résumé
Properdin is the only positive regulator of the complement system. In this study, we characterize the prevalence, functional consequences and disease associations of autoantibodies against properdin in a cohort of patients with autoimmune disease systemic lupus erythematosus (SLE) suffering from lupus nephritis (LN). We detected autoantibodies against properdin in plasma of 22·5% of the LN patients (16 of 71) by enzyme-linked immunosorbent assay (ELISA). The binding of these autoantibodies to properdin was dose-dependent and was validated by surface plasmon resonance. Higher levels of anti-properdin were related to high levels of anti-dsDNA and anti-nuclear antibodies and low concentrations of C3 and C4 in patients, and also with histological signs of LN activity and chronicity. The high negative predictive value (NPV) of anti-properdin and anti-dsDNA combination suggested that patients who are negative for both anti-properdin and anti-dsDNA will not have severe nephritis. Immunoglobulin G from anti-properdin-positive patients' plasma increased the C3b deposition on late apoptotic cells by flow cytometry. Nevertheless, these IgGs did not modify substantially the binding of properdin to C3b, the C3 convertase C3bBb and the pro-convertase C3bB, evaluated by surface plasmon resonance. In conclusion, anti-properdin autoantibodies exist in LN patients. They have weak but relevant functional consequences, which could have pathological significance.
Identifiants
pubmed: 32306375
doi: 10.1111/cei.13443
pmc: PMC7366743
doi:
Substances chimiques
Antibodies, Antinuclear
0
Antigen-Antibody Complex
0
Autoantibodies
0
Complement C3
0
Complement C4
0
Immunoglobulin G
0
Properdin
11016-39-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
135-144Informations de copyright
© 2020 British Society for Immunology.
Références
Curr Drug Targets. 2008 Feb;9(2):158-64
pubmed: 18288967
FEBS J. 2010 Jul;277(14):3039-50
pubmed: 20546303
Arthritis Res Ther. 2009;11(3):R87
pubmed: 19515233
Ann Rheum Dis. 2005 Mar;64(3):444-8
pubmed: 15286009
Lupus. 2011 Oct;20(12):1267-74
pubmed: 21813587
J Clin Invest. 1975 Sep;56(3):761-7
pubmed: 1159085
Dis Markers. 2015;2015:450351
pubmed: 26549923
Immunol Lett. 2014 Aug;160(2):163-71
pubmed: 24491679
J Biol Chem. 2011 Feb 18;286(7):5359-67
pubmed: 21135110
Front Immunol. 2019 Sep 04;10:2097
pubmed: 31552043
J Immunol. 2015 Jun 1;194(11):5129-38
pubmed: 25917093
Med Microbiol Immunol. 2014 Aug;203(4):257-71
pubmed: 24728387
Immun Inflamm Dis. 2017 Jan 26;5(1):68-77
pubmed: 28250926
Lupus. 2011 Jan;20(1):28-34
pubmed: 20943718
Q J Med. 1993 Jul;86(7):447-58
pubmed: 8210301
BMC Nephrol. 2013 Mar 19;14:63
pubmed: 23510032
J Biol Chem. 1984 Apr 10;259(7):4582-8
pubmed: 6707020
J Immunol. 1989 Jan 1;142(1):202-7
pubmed: 2909614
PLoS One. 2015 Apr 16;10(4):e0123572
pubmed: 25881125
J Am Soc Nephrol. 2017 May;28(5):1603-1613
pubmed: 28096309
J Immunol Res. 2015;2015:106904
pubmed: 25815344
Annu Rev Immunol. 2010;28:131-55
pubmed: 19947883
Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E534-E539
pubmed: 28069958
Lupus. 2015 Jan;24(1):42-9
pubmed: 25124676
Clin Exp Immunol. 1974 Apr;16(4):575-81
pubmed: 4219766
Curr Opin Nephrol Hypertens. 2009 May;18(3):220-5
pubmed: 19374008
Front Immunol. 2019 Aug 22;10:2007
pubmed: 31507604
Clin Immunol Immunopathol. 1990 Aug;56(2):226-38
pubmed: 2143128
J Am Soc Nephrol. 2004 Feb;15(2):241-50
pubmed: 14747370
J Immunol. 2007 Aug 15;179(4):2600-8
pubmed: 17675523
Rheumatology (Oxford). 2005 Jul;44(7):902-6
pubmed: 15814577
Nephrol Dial Transplant. 2019 May 1;34(5):742-750
pubmed: 30053164
BMC Nephrol. 2015 Mar 30;16:40
pubmed: 25886501
J Immunol. 2008 Jun 1;180(11):7613-21
pubmed: 18490764
Front Immunol. 2019 Jan 29;10:64
pubmed: 30761135
Am J Physiol Renal Physiol. 2008 Nov;295(5):F1397-403
pubmed: 18753294
PLoS One. 2014 Mar 25;9(3):e92404
pubmed: 24667818
J Biol Chem. 2015 Oct 16;290(42):25343-55
pubmed: 26245903
Kidney Int. 2017 Nov;92(5):1232-1241
pubmed: 28712854
Rheumatol Int. 2012 Aug;32(8):2445-51
pubmed: 21706294